Test Bank Pharmacotherapeutics for Advanced Practice Nurse Prescribers 6e Teri Moser Woo
b b b b b b b b b b b
Woo 1
Pharmacotherapeutics bfor bAPN bPrescribers, b6e Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
b b b b b b b b b b
MULTIPLE bCHOICE
1. Nurse bpractitioner bprescriptive bauthority bis bregulated bby:
A. The bNational bCouncil bof bState bBoards bof bNursing
B. The bU.S. bDrug bEnforcement bAdministration
C. The bState bBoard bof bNursing bfor beach bstate
D. The bState bBoard bof bPharmacy
ANS: b C PTS: b 1
2. The bbenefits bto bthe bpatient bof bhaving ban badvanced bpractice bregistered bnurse b(APRN)
prescriberbinclude:
b
A. Nurses bknow bmore babout bpharmacology bthan bother bprescribers bbecause bthey btake
bitb
both bin btheir bbasic bnursing bprogram band bin btheir bAPRN bprogram.
B. Nurses bcare bfor bthe bpatient bfrom ba bholistic bapproach band binclude bthe bpatient
binb decision-making bregarding btheir bcare.
C. APRNs bare bless blikely bto bprescribe bnarcotics band bother bcontrolled bsubstances.
D. APRNs bare bable bto bprescribe bindependently bin ball bstates, bwhereas ba
bphysician’sb assistant bneeds bto bhave ba bphysician bsupervising btheir bpractice.
ANS: b B PTS: b 1
3. Clinical bjudgment bin bprescribing bincludes:
A. Factoring bin bthe bcost bto bthe bpatient bof bthe bmedication bprescribed
B. Always bprescribing bthe bnewest bmedication bavailable bfor bthe bdisease bprocess
C. Handing bout bdrug bsamples bto bpoor bpatients
D. Prescribing ball bgeneric bmedications bto bcut bcosts
ANS: b A PTS: b 1
4. The bprocess bfor bchoosing ban beffective bdrug bfor ba bdisorder bincludes:
A. Asking bthe bpatient bwhat bdrug bthey bthink bwould bwork bbest bfor bthem
B. Consulting bnationally brecognized bguidelines bfor bdisease bmanagement
C. Prescribing bmedications bthat bare bavailable bas bsamples bbefore bwriting ba bprescription
D. Following bU.S. bDrug bEnforcement bAdministration bguidelines bfor bprescribing
ANS: b B PTS: b 1
5. Nonintentional bnonadherence bof bdrug btherapy bmay boccur bdue bto:
A. Belief bthat bmedication bdoes bnot bwork
B. Adverse bdrug breactions
C. Chronic bconditions bthat brequire bdaily btherapy
D. Forgetfulness bor bdistraction
ANS: b D PTS: b 1
, Woo 1
Pharmacotherapeutics bfor bAPN bPrescribers, Ch02
b6e
Chapter 2. Review of Basic Principles of Pharmacology
b b b b b b b
MULTIPLE bCHOICE
1. A bpatient’s bnutritional bintake band blaboratory bresults breflect bhypoalbuminemia. bThis bis
criticalbto bprescribing bbecause:
b
A. Distribution bof bdrugs bto btarget btissue bmay bbe baffected.
B. The bsolubility bof bthe bdrug bwill bnot bmatch bthe bsite bof babsorption.
C. There bwill bbe bless bfree bdrug bavailable bto bgenerate ban beffect.
D. Drugs bbound bto balbumin bare breadily bexcreted bby bthe bkidneys.
ANS: b A PTS: b 1
2. Drugs bthat bhave ba bsignificant bfirst-pass beffect:
A. Must bbe bgiven bby bthe benteral b(oral) broute bonly
B. Bypass bthe bhepatic bcirculation
C. Are brapidly bmetabolized bby bthe bliver band bmay bhave blittle, bif bany, bdesired baction
D. Are bconverted bby bthe bliver bto bmore bactive band bfat-soluble bforms
ANS: b C PTS: b 1
3. The broute bof bexcretion bof ba bvolatile bdrug bwill blikely bbe bthe:
A. Kidneys
B. Lungs
C. Bile band bfeces
D. Skin
ANS: b B PTS: b 1
4. A bmajor bdisadvantage bto bIV badministration bis bthat:
A. First-pass bmetabolism bis beliminated.
B. Needles band bsterility bare brequired.
C. Absorption bof bthe bdrug bcannot bbe bslowed bafter badministration.
D. It bis bsignificantly bmore bexpensive bthan bother broutes.
ANS: b C PTS: b b b 1
5. The bnurse bpractitioner b(NP) bchooses bto bgive bcephalexin bevery b8 bhours bbased bon bknowledge
bofbthe bdrug’s:
A. Propensity bto bgo bto bthe btarget breceptor
B. Biological bhalf-life
C. Pharmacodynamics
D. Safety band bside beffects
ANS: b B PTS: b 1
6. Deferasirox bis ba bchelating bagent bused bto btreat biron boverload bby bbinding biron bto
brender bitbbiologically binactive. bThis bis bbest bcharacterized bas ba(n):
, Woo 2
Pharmacotherapeutics bfor bAPN bPrescribers, Ch02
b6e
A. Nonreceptor bmechanism
B. Partial bagonist
C. Full bagonist
D. Noncompetitive bantagonist
ANS: b A PTS: b 1
7. The bpoint bin btime bon bthe bdrug bconcentration bcurve bthat bindicates bthe bfirst bsign bof ba
therapeuticbeffect bis bthe:
b
A. Minimum badverse beffect blevel
B. Peak bof baction
C. Onset bof baction
D. Therapeutic brange
ANS: b C PTS: b 1
8. Phenytoin brequires bthat ba btrough blevel bbe bdrawn. bPeak band btrough blevels bare bdone:
A. When bthe bdrug bhas ba bwide btherapeutic brange
B. When bthe bdrug bwill bbe badministered bfor ba bshort btime bonly
C. When bthere bis ba bhigh bcorrelation bbetween bthe bdose band bsaturation bof breceptor bsites
D. To bdetermine bif ba bdrug bis bin bthe btherapeutic brange
ANS: b D PTS: b 1
9. A blaboratory bresult bindicates bthat bthe bpeak blevel bfor ba bdrug bis babove bthe bminimum
toxicbconcentration. bThis bmeans bthat bthe:
b
A. Concentration bwill bproduce btherapeutic beffects.
B. Concentration bwill bproduce ban badverse bresponse.
C. Time bbetween bdoses bmust bbe bshortened.
D. Duration bof baction bof bthe bdrug bis btoo blong.
ANS: b B PTS: b 1
10. Drugs bthat bare breceptor bagonists bmay bdemonstrate bwhat bproperty?
A. Irreversible bbinding bto bthe bdrug breceptor bsite
B. Up-regulation bwith bchronic buse
C. Desensitization bor bdown-regulation bwith bcontinuous buse
D. Inverse brelationship bbetween bdrug bconcentration band bdrug baction
ANS: b C PTS: b 1
11. Drugs bthat bare breceptor bantagonists, bsuch bas bbeta bblockers, bmay bcause:
A. Down-regulation bof bthe bdrug breceptor
B. An bexaggerated bresponse bif babruptly bdiscontinued
C. Partial bblockade bof bthe beffects bof bagonist bdrugs
D. An bexaggerated bresponse bto bcompetitive bdrug bagonists
ANS: b B PTS: b 1
, Woo 3
Pharmacotherapeutics bfor bAPN bPrescribers, Ch02
b6e
12. Factors bthat baffect bgastric bdrug babsorption binclude:
A. Liver benzyme bactivity
B. Protein-binding bproperties bof bthe bdrug bmolecule
C. Lipid bsolubility bof bthe bdrug
D. Ability bto bchew band bswallow
ANS: b C PTS: b 1
13. Drugs badministered bvia bIV:
A. Need bto bbe blipid bsoluble bin border bto bbe beasily babsorbed
B. Begin bdistribution binto bthe bbody bimmediately
C. Are beasily babsorbed bif bthey bare bnonionized
D. May buse bpinocytosis bto bbe babsorbed
ANS: b B PTS: b 1
14. When ba bmedication bis badded bto ba bregimen bfor ba bsynergistic beffect, bthe bcombined beffect bof
bthebdrugs bis:
A. The bsum bof bthe beffects bof beach bdrug bindividually
B. Greater bthan bthe bsum bof bthe beffects bof beach bdrug bindividually
C. Less bthan bthe beffect bof beach bdrug bindividually
D. Not bpredictable, bas bit bvaries bwith beach bindividual
ANS: b B PTS: b 1
15. Which bof bthe bfollowing bstatements babout bbioavailability bis btrue?
A. Bioavailability bissues bare bespecially bimportant bfor bdrugs bwith bnarrow
therapeuticbranges bor bsustained-release bmechanisms.
b
B. All bbrands bof ba bdrug bhave bthe bsame bbioavailability.
C. Drugs bthat bare badministered bmore bthan bonce ba bday bhave bgreater bbioavailability
thanbdrugs bgiven bonce bdaily.
b
D. Combining ban bactive bdrug bwith ban binert bsubstance bdoes bnot baffect bbioavailability.
ANS: b A PTS: b 1
16. Which bof bthe bfollowing bstatements babout bthe bmajor bdistribution bbarriers b(blood–brain bor
bfetal–bplacental) bis btrue?
A. Water bsoluble band bionized bdrugs bcross bthese bbarriers brapidly.
B. The bblood–brain bbarrier bslows bthe bpassage bof bmany bdrugs binto band bout bof
bbrainbcells.
C. The bfetal–placental bbarrier bprotects bthe bfetus bfrom bdrugs btaken bby bthe bmother.
D. Lipid-soluble bdrugs bdo bnot bpass bthese bbarriers band bare bsafe bfor bpregnant bwomen.
ANS: b B PTS: b 1
17. Drugs bare bmetabolized bmainly bby bthe bliver bvia bphase bI bor bphase bII breactions. bThe bpurpose
ofbboth bof bthese btypes bof breactions bis bto:
b
A. Inactivate bprodrugs bbefore bthey bcan bbe bactivated bby btarget btissues
b b b b b b b b b b b
Woo 1
Pharmacotherapeutics bfor bAPN bPrescribers, b6e Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
b b b b b b b b b b
MULTIPLE bCHOICE
1. Nurse bpractitioner bprescriptive bauthority bis bregulated bby:
A. The bNational bCouncil bof bState bBoards bof bNursing
B. The bU.S. bDrug bEnforcement bAdministration
C. The bState bBoard bof bNursing bfor beach bstate
D. The bState bBoard bof bPharmacy
ANS: b C PTS: b 1
2. The bbenefits bto bthe bpatient bof bhaving ban badvanced bpractice bregistered bnurse b(APRN)
prescriberbinclude:
b
A. Nurses bknow bmore babout bpharmacology bthan bother bprescribers bbecause bthey btake
bitb
both bin btheir bbasic bnursing bprogram band bin btheir bAPRN bprogram.
B. Nurses bcare bfor bthe bpatient bfrom ba bholistic bapproach band binclude bthe bpatient
binb decision-making bregarding btheir bcare.
C. APRNs bare bless blikely bto bprescribe bnarcotics band bother bcontrolled bsubstances.
D. APRNs bare bable bto bprescribe bindependently bin ball bstates, bwhereas ba
bphysician’sb assistant bneeds bto bhave ba bphysician bsupervising btheir bpractice.
ANS: b B PTS: b 1
3. Clinical bjudgment bin bprescribing bincludes:
A. Factoring bin bthe bcost bto bthe bpatient bof bthe bmedication bprescribed
B. Always bprescribing bthe bnewest bmedication bavailable bfor bthe bdisease bprocess
C. Handing bout bdrug bsamples bto bpoor bpatients
D. Prescribing ball bgeneric bmedications bto bcut bcosts
ANS: b A PTS: b 1
4. The bprocess bfor bchoosing ban beffective bdrug bfor ba bdisorder bincludes:
A. Asking bthe bpatient bwhat bdrug bthey bthink bwould bwork bbest bfor bthem
B. Consulting bnationally brecognized bguidelines bfor bdisease bmanagement
C. Prescribing bmedications bthat bare bavailable bas bsamples bbefore bwriting ba bprescription
D. Following bU.S. bDrug bEnforcement bAdministration bguidelines bfor bprescribing
ANS: b B PTS: b 1
5. Nonintentional bnonadherence bof bdrug btherapy bmay boccur bdue bto:
A. Belief bthat bmedication bdoes bnot bwork
B. Adverse bdrug breactions
C. Chronic bconditions bthat brequire bdaily btherapy
D. Forgetfulness bor bdistraction
ANS: b D PTS: b 1
, Woo 1
Pharmacotherapeutics bfor bAPN bPrescribers, Ch02
b6e
Chapter 2. Review of Basic Principles of Pharmacology
b b b b b b b
MULTIPLE bCHOICE
1. A bpatient’s bnutritional bintake band blaboratory bresults breflect bhypoalbuminemia. bThis bis
criticalbto bprescribing bbecause:
b
A. Distribution bof bdrugs bto btarget btissue bmay bbe baffected.
B. The bsolubility bof bthe bdrug bwill bnot bmatch bthe bsite bof babsorption.
C. There bwill bbe bless bfree bdrug bavailable bto bgenerate ban beffect.
D. Drugs bbound bto balbumin bare breadily bexcreted bby bthe bkidneys.
ANS: b A PTS: b 1
2. Drugs bthat bhave ba bsignificant bfirst-pass beffect:
A. Must bbe bgiven bby bthe benteral b(oral) broute bonly
B. Bypass bthe bhepatic bcirculation
C. Are brapidly bmetabolized bby bthe bliver band bmay bhave blittle, bif bany, bdesired baction
D. Are bconverted bby bthe bliver bto bmore bactive band bfat-soluble bforms
ANS: b C PTS: b 1
3. The broute bof bexcretion bof ba bvolatile bdrug bwill blikely bbe bthe:
A. Kidneys
B. Lungs
C. Bile band bfeces
D. Skin
ANS: b B PTS: b 1
4. A bmajor bdisadvantage bto bIV badministration bis bthat:
A. First-pass bmetabolism bis beliminated.
B. Needles band bsterility bare brequired.
C. Absorption bof bthe bdrug bcannot bbe bslowed bafter badministration.
D. It bis bsignificantly bmore bexpensive bthan bother broutes.
ANS: b C PTS: b b b 1
5. The bnurse bpractitioner b(NP) bchooses bto bgive bcephalexin bevery b8 bhours bbased bon bknowledge
bofbthe bdrug’s:
A. Propensity bto bgo bto bthe btarget breceptor
B. Biological bhalf-life
C. Pharmacodynamics
D. Safety band bside beffects
ANS: b B PTS: b 1
6. Deferasirox bis ba bchelating bagent bused bto btreat biron boverload bby bbinding biron bto
brender bitbbiologically binactive. bThis bis bbest bcharacterized bas ba(n):
, Woo 2
Pharmacotherapeutics bfor bAPN bPrescribers, Ch02
b6e
A. Nonreceptor bmechanism
B. Partial bagonist
C. Full bagonist
D. Noncompetitive bantagonist
ANS: b A PTS: b 1
7. The bpoint bin btime bon bthe bdrug bconcentration bcurve bthat bindicates bthe bfirst bsign bof ba
therapeuticbeffect bis bthe:
b
A. Minimum badverse beffect blevel
B. Peak bof baction
C. Onset bof baction
D. Therapeutic brange
ANS: b C PTS: b 1
8. Phenytoin brequires bthat ba btrough blevel bbe bdrawn. bPeak band btrough blevels bare bdone:
A. When bthe bdrug bhas ba bwide btherapeutic brange
B. When bthe bdrug bwill bbe badministered bfor ba bshort btime bonly
C. When bthere bis ba bhigh bcorrelation bbetween bthe bdose band bsaturation bof breceptor bsites
D. To bdetermine bif ba bdrug bis bin bthe btherapeutic brange
ANS: b D PTS: b 1
9. A blaboratory bresult bindicates bthat bthe bpeak blevel bfor ba bdrug bis babove bthe bminimum
toxicbconcentration. bThis bmeans bthat bthe:
b
A. Concentration bwill bproduce btherapeutic beffects.
B. Concentration bwill bproduce ban badverse bresponse.
C. Time bbetween bdoses bmust bbe bshortened.
D. Duration bof baction bof bthe bdrug bis btoo blong.
ANS: b B PTS: b 1
10. Drugs bthat bare breceptor bagonists bmay bdemonstrate bwhat bproperty?
A. Irreversible bbinding bto bthe bdrug breceptor bsite
B. Up-regulation bwith bchronic buse
C. Desensitization bor bdown-regulation bwith bcontinuous buse
D. Inverse brelationship bbetween bdrug bconcentration band bdrug baction
ANS: b C PTS: b 1
11. Drugs bthat bare breceptor bantagonists, bsuch bas bbeta bblockers, bmay bcause:
A. Down-regulation bof bthe bdrug breceptor
B. An bexaggerated bresponse bif babruptly bdiscontinued
C. Partial bblockade bof bthe beffects bof bagonist bdrugs
D. An bexaggerated bresponse bto bcompetitive bdrug bagonists
ANS: b B PTS: b 1
, Woo 3
Pharmacotherapeutics bfor bAPN bPrescribers, Ch02
b6e
12. Factors bthat baffect bgastric bdrug babsorption binclude:
A. Liver benzyme bactivity
B. Protein-binding bproperties bof bthe bdrug bmolecule
C. Lipid bsolubility bof bthe bdrug
D. Ability bto bchew band bswallow
ANS: b C PTS: b 1
13. Drugs badministered bvia bIV:
A. Need bto bbe blipid bsoluble bin border bto bbe beasily babsorbed
B. Begin bdistribution binto bthe bbody bimmediately
C. Are beasily babsorbed bif bthey bare bnonionized
D. May buse bpinocytosis bto bbe babsorbed
ANS: b B PTS: b 1
14. When ba bmedication bis badded bto ba bregimen bfor ba bsynergistic beffect, bthe bcombined beffect bof
bthebdrugs bis:
A. The bsum bof bthe beffects bof beach bdrug bindividually
B. Greater bthan bthe bsum bof bthe beffects bof beach bdrug bindividually
C. Less bthan bthe beffect bof beach bdrug bindividually
D. Not bpredictable, bas bit bvaries bwith beach bindividual
ANS: b B PTS: b 1
15. Which bof bthe bfollowing bstatements babout bbioavailability bis btrue?
A. Bioavailability bissues bare bespecially bimportant bfor bdrugs bwith bnarrow
therapeuticbranges bor bsustained-release bmechanisms.
b
B. All bbrands bof ba bdrug bhave bthe bsame bbioavailability.
C. Drugs bthat bare badministered bmore bthan bonce ba bday bhave bgreater bbioavailability
thanbdrugs bgiven bonce bdaily.
b
D. Combining ban bactive bdrug bwith ban binert bsubstance bdoes bnot baffect bbioavailability.
ANS: b A PTS: b 1
16. Which bof bthe bfollowing bstatements babout bthe bmajor bdistribution bbarriers b(blood–brain bor
bfetal–bplacental) bis btrue?
A. Water bsoluble band bionized bdrugs bcross bthese bbarriers brapidly.
B. The bblood–brain bbarrier bslows bthe bpassage bof bmany bdrugs binto band bout bof
bbrainbcells.
C. The bfetal–placental bbarrier bprotects bthe bfetus bfrom bdrugs btaken bby bthe bmother.
D. Lipid-soluble bdrugs bdo bnot bpass bthese bbarriers band bare bsafe bfor bpregnant bwomen.
ANS: b B PTS: b 1
17. Drugs bare bmetabolized bmainly bby bthe bliver bvia bphase bI bor bphase bII breactions. bThe bpurpose
ofbboth bof bthese btypes bof breactions bis bto:
b
A. Inactivate bprodrugs bbefore bthey bcan bbe bactivated bby btarget btissues
